

## DAFTAR PUSTAKA

- Aryandono, T., Epidemiologi, Faktor Resiko, Genetik dan Skrining Kanker Payudara. Diunduh dari: [www.4shared.com/Epidemiologi\\_faktor\\_resiko\\_gen.html](http://www.4shared.com/Epidemiologi_faktor_resiko_gen.html). Update terakhir: 25 juli 2008.
- American Cancer Society. Cancer Facts and Figures 2011. Available from: [www.cancer.gov](http://www.cancer.gov). . Last accessed July 27, 2011.
- American Cancer Society. 2010. Breast Cancer. Available from: [www.cancer.org](http://www.cancer.org). Accessed on: December 15, 2011. Last update on: Juny 3, 2012
- Azamris. 2006. Analisis Faktor Risiko pada Pasien Kanker Payudara di Rumah Sakit Dr. M. Djamil Padang. Cermin Dunia Kedokteran No. 152.
- [Barcenas, C.H.](#), [Wells, J.](#), [Chong, D.](#) 2010. Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry. *Clin Breast Cancer*. 10(1):59-63.
- Brown, N.S., Bicknell, R. 2011. Hypoxia and oxidative stress in breast cancer Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res*. 3:323–327.
- Cancer Research UK. Breast Cancer-UK. Available from: <http://info.cancerresearchuk.org/>. Last update: May 2009.
- Dahlui, M., Ramli, S., Bulgiba, A. 2011. Breast Cancer Prevention and Control Programs in Malaysia. *Asian Pacific J Cancer Prev*. 12: 1631-1634
- Davey, P. 2005. Kanker Payudara. *At a Glance Medicine*. Erlangga. Jakarta. 173-174.
- Decock, J., Paridaens, R., Ye, S. 2008. Genetic Polymorphisms of Matrix Metalloproteinases in Lung, Breast and Colorectal Cancer. *Clin Genet*. 73:197-221.
- Desen, W., Japaries, W. 2011. Tumor Daerah Toraks. *Buku Ajar Onkologi Klinik*. Edisi 2. Balai Penerbit FKUI. Jakarta.

- Economist Intelligence Unit. 2009. Breakaway: The global burden of cancer-challenges and opportunities. Available from: <http://livestrongblog.org/>.
- Eroschenko, V.P. 2003. Kelenjar Mammae. *Atlas Histologi di Fiore dengan Korelasi Fungsional*. Edisi 9. EGC. Jakarta. 327-329
- Faiz, O., Moffat D. 2004. Drainase Vena dan Limfatik Ekstremitas Atas dan Payudara. *At a Glance Series Anatomi*. Erlangga. Jakarta. 64-65
- Fan, SQ., Wei, QY., Li, MR., Zhang, LQ. 2003. Expression and clinical significance of MMP-2, MMP-9, TIMP-1, and TIMP-2 in breast carcinoma. *Ai Zheng*. 22(9):968-73
- Garbett, E.A., Reed, M. W., Stephenson, T.J., Brown, N.J. 2000. Proteolysis in human breast cancer. *Mol Pathol*. 53(2): 99–106.
- Goodsell, D.S. 1999. The Molecular Perspective: Matrix metalloproteinase 2. *The Oncologist*. 4960; 509-11.
- Greene, F.L., Page, D.L., Fleming, I.D., et. al. 2002. *AJCC Cancer Staging Manual*. Sixth Ed. Springer. Philadelphia. 225-230.
- Hardjoeno, dkk. 2003. Tumor Marker. *Interpretasi Hasil Tes Laboratorium Diagnostik*. Lembaga Penerbitan Universitas Hasanuddin. Makassar. 421-423.
- Heffner, LJ., Schust, DJ. 2005. *At a Glance: Sistem Reproduksi*. Edisi Kedua. Jakarta: Erlangga Medical Series.
- Hemati, S., Sadeghi, M., Motovali-Bashi, M., et al. 2010. Higher plasma MMP-9 level in breast cancer patients with MMP-9 promoter T allele. *J. Biol. Res.-Thessalon*. 13: 113 – 118.
- Hornebeck, W, Lambert E, Petitfrère E, et al. 2005. Beneficial and detrimental influences of Tissue Inhibitors of Metalloproteinases-1 (TIMP-1) in Tumor Progression. *Biochimie*. 87:377-383
- Hukom, R.A., 2003. Risiko Kanker Payudara Ditinjau dari Segi Epidemiologi. *Penatalaksanaan Kanker Payudara Terkini*. (Tim Penanggulangan & Pelayanan Kanker Payudara Terpadu Paripurna R.S. Kanker Dharmais). Jakarta: Pustaka Populer Obor: 1-9

- Hunt, K.K., Rob, G.L., Strom, E.A., et.al. 2008. *Breast Cancer*. Second Edition. Springer. Philadelphia. P: 1-18.
- Jakowlew, S.B. 2008. *Transforming Growth Faktor- $\beta$  in Cancer Terapy: Basic and Clinical Biology*. Humana Press. New Jersey.
- Jiang, Y, Goldberg ID, Shi YE. 2002. *Complex Roles of Tissue Inhibitors of Metalloproteinases in Cancer*. *Oncogene*. 21:2245-2252
- Jinga, DC, Bilidaru, Condrea I et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in Breast Cancer: Correlations with Prognostic Factor. *J.Cell.Mol. Med*. 10(2):499-510
- Jordan, M. 2003. *Managing Breast Cancer Risk*. BC Decker Inc. New York. 3-15.
- Juranah. Bahrun U, Pakasi RDN. 2012. Analisis kadar Interleukin-8 pada penderita Carcinoma Mammae
- Kersten, K. 2011. Predicting Breast Cancer Metastasis; Formation of the Pre-metastatic Niche. Available from: <http://igitur-archive.library.uu.nl/>. Access: Oct 30, 2011.
- Kim, B. 1995. Cigarette Smoking and Breast. *BMJ*. 9: 1431-1433.
- Kim, K., Kim, J.W. 2007. Tumor Metastasis: matriks metalloproteinase-9 (MMP-9). *BioWave*. 9 (1): 1-15.
- Klein, G., Vellenga E., Fraaji, MW, Kramps, WA, Bont, ES. 2004. The Possible Role of Matrix Metalloproteinase (MMP-2) and MMP-9 in Cancer, e.g. Acute Leukemia. *Critical Reviews in Oncology/Hematology*. 50:87-100
- Kresno, S.B. 2011. Ilmu Dasar Onkologi. Badan Penerbit FKUI. Jakarta
- Kumar, V., Cotran, R.S., Robbins, S.L. 2007. *Buku Ajar Patologi Robbins*. Edisi 7. EGC. Jakarta. 199-215.
- Kuvaja, P. 2007. The Prognostic Role of Matrix Metalloproteinases MMP-2 and -9 and Their Inhibitors TIMP-1 and-2 in Primary breast cancer. University of Oulu. 1-85
- Lee, M.H., Murphy, G. 2004. Matrix Metalloproteinases at a Glance. *Journal of Cell Science*. 117: 4015-6.

- Lippman, M.E., Dickson R.B. 1998. *Breast Cancer: Cellular and Molecular Biology*. Kluwer Academic Publishers. Boston. 1-9.
- Mayer, M. 2003. Treatment and Outcomes for High-risk and Metastatic Breast Cancer in California: An Inquiry into Disparities and Research Needs.
- Menghadam, A.F., Stieber, P. 1996. General Criteria for the Use of Tumour Markers in Sensible Use of Tumour Markers. Roche. Switzerland. 11-31
- Nagase, H, Visse R, Murphy G. 2006. Structure and function of Matrix Metalloproteinases and TIMPs. *Cardiovasc Res*. 69:562-573
- O-charoenrat, P., Rhys-Evans, P.H., Eccles, S.A. 2001. Expression of Matrix Metalloproteinases and their inhibitors Correlates with Invasion and Metastasis in Squamous Cell Carcinoma of the Head and Neck. *Arch Otolaryngol Head Neck Surg*. 127: 813-20.
- Provatopoulou, X., Gounaris, A., Kalogera, E. 2009. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. *BMC Cancer*. 9:390.
- Quaranta, M., Daniele, A., Coviello, M., et al. 2007. MMP-2, MMP-9, VEGF and CA 15.3 in Breast Cancer. *Anticancer Res*. 27: 3593-3600
- Rasjidi, I. 2010. *Kanker Payudara. 100 Question & Answer Kanker pada Wanita*. PT Gramedia. Jakarta. 17-35.
- Rundhaug, J.E. 2003. Matrix metalloproteinase, Angiogenesis and Cancer. *Clin Cancer Res*. 9: 551-554.
- Schwartz, S.I. 2000. *Intisari Prinsip-prinsip Ilmu Bedah*. EGC. Jakarta. 227-230.
- Schoenfeld, E.R., O'Leary, E.S., Henderson, K. 2003. Electromagnetic Fields and Breast Cancer on Long Island: A Case-Control Study. *Am J Epidemiol*. 158:47-58.
- Scottish Intercollegiate Guidelines Network. 2005. Management of Breast Cancer in Women: A National Clinical Guidelines. [www.sign.ac.uk](http://www.sign.ac.uk). Accessed September 27, 2011.

- Sevianty, S., Bahrin U, Pakasi RDN. 2011. Analisis Nilai 5-Hydroxyindoleacetic Acid (5-HIAA) pada Penderita Carcinoma Mammae.
- Siege, R, Naishadham D, Jemal A.2012. Cancer Statistics, 2012. <http://cacancerjournal.com>. Accessed February 22,2013.
- Somiari, S.B., Somiari, R.I., Heckman, C.M. 2006. Circulating MMP2 and MMP9 in breast cancer—Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. *IJC*. 119: 1403-1411.
- Stebbing, J and Ngan, S. 2010. Breast cancer (metastatic). <http://clinicalevidence.bmj.com>. Last update: September 8, 2010. Accessed: January 3, 2012.
- Stephen, S., Legare, R.D. 2002. Risk Factor for Breast Cancer. *Obstetry and Gynecology Clinics*. Saunders Company. Philadelphia.
- Stuelten, C.H., Byfield, S.D., Arany, P.R., et.al. 2005. Breast Cancer Cells Induce Stromal Fibroblast to Express MMP-9 via Secretion of TNF- $\alpha$  and TGF- $\beta$ . *Journal of Cell Science*. 118: 2143-2153.
- Subarkah, A., 2008. Kanker Payudara. Diunduh dari: [www.klinikindonesia.com](http://www.klinikindonesia.com). Diakses 9 Agustus 2011.
- Swain, S.M. 2006. *Inflammatory Breast Cancer*. IOS Press. 25-30.
- Tjindarbumi, D. 2000. Deteksi dini kanker payudara dan penanggulangannya. Dalam Ramli M, Umbas R, Panogoro SS ads. Deteksi Dini Kanker, Balai penerbit FK-UI, Jakarta:32-43
- Thraikill, K., Cockrell, G., Simpson, P. 2006. Physiological Matrix Metalloproteinase (MMP) Concentration: Comparison of Serum and Plasma Specimens. *Clin Chem Lab Med*. 44(4): 503-504.
- Valentina, L. 2007. *Aplikasi Klinis Patofisiologi: Pemeriksaan dan Manajemen*. EGC. Jakarta. 127-132
- Vogl, M., Muller, MM. 2002. Tumor Markers: review and Clinical Applications. *IFCC*, 5-30
- Wildana, Bahrin U, Arif M. 2012. Analisis Kadar Matrix Metalloproteinase-9 pada penderita Carsinoma Mammae

Wu, Z.S., Wu, Q., Yang, J.H. 2008. Prognostic Significance Of MMP-9 And TIMP-1 Serum And Tissue Expression In Breast Cancer. *IJC*. 122: 2050-2056.



**KEMENTERIAN PENDIDIKAN NASIONAL  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEDOKTERAN  
KOMISI ETIK PENELITIAN KESEHATAN**

Sekretariat : Lantai 3 Gedung Laboratorium Terpadu  
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10, Makassar. Telp. (0411)5780103, Fax (0411) 581431.  
Contact person **dr. Agussalim Bukhari,PhD,SpGK** (HP. 081241850858), email: agussalimbukhari@yahoo.com

**REKOMENDASI PERSETUJUAN ETIK**  
Nomor : 1211 /H4.8.4.5.31/PP36-KOMETIK/2013

Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Hasanuddin, setelah melalui pembahasan dan penilaian, pada rapat tertanggal **26 Juni 2013**, telah memutuskan, protokol penelitian berjudul:

*Perbandingan Rasio Matrix Metalloproteinase-9 dan Tissue of Inhibitor  
Metalloproteinase-1 Berdasarkan Stadium Carcinoma Mammiae*

dengan Peneliti Utama: **dr. Erviani Zuhriah**

No. Register

U	H	1	3	0	5	0	2	3	4
---	---	---	---	---	---	---	---	---	---

yang diterima pada tanggal: **30 Mei 2013**

Perbaikan diterima tanggal: **25 Juli 2013**

**dapat disetujui untuk dilaksanakan di RS dr. Wahidin Sudirohusodo dan Unit Penelitian Unhas di Makassar.**

Persetujuan Etik ini berlaku sejak tanggal ditetapkan sampai dengan batas waktu pelaksanaan penelitian.

Pada akhir penelitian, **laporan pelaksanaan penelitian** harus diserahkan kepada KEPK Fakultas Kedokteran Unhas. Jika ada perubahan protokol dan /atau perpanjangan penelitian, harus mengajukan kembali permohonan kajian etik penelitian (amandemen protokol).

Makassar, 28 Agustus 2013

**Komisi Etik Penelitian Kesehatan Fak. Kedokteran Unhas**

Ketua

**Prof. Dr. dr. Suryani As'ad, M.Sc, Sp.GK**  
NIP 19600504 1986 01 2 002



Sekretaris

**dr. Agussalim B. MMed, Ph.D, SpGK**  
NIP 19700821 1999 03 1 001

## Lampiran 2. Formulir Persetujuan Mengikuti Penelitian

**SURAT PERSETUJUAN**

Setelah mendapat penjelasan mengenai maksud, tujuan dan manfaat penelitian dengan judul: **“Perbandingan rasio *Matrix Metalloproteinase-9 (MMP-9)* dan *Tissue Inhibitors of metalloproteinase-1 (TIMP-1)* pada *Carcinoma mammae*”** ; maka saya yang bertanda tangan di bawah ini:

Nama :

Umur :

Alamat :

Menyetujui dan bersedia ikut serta dalam penelitian ini. Bila suatu waktu saya merasa dirugikan dalam bentuk apapun, saya berhak menghentikan peran serta saya dalam penelitian ini kapan saja dengan memberitahukan kepada peneliti.

Demikian pernyataan persetujuan ini saya buat dalam keadaan sadar dan tanpa paksaan dari pihak manapun.

Makassar, .....2013

Peneliti

Peserta Penelitian

(dr. Erviani Zuhriah)

( )



## Lampiran 3

## DATA DASAR PENELITIAN

NO	NAMA	UMUR (Tahun)	STADIUM	TNM	KADAR MMP-9 (ng/mL)	KADAR TIMP-1 (ng/mL)	RASIO MMP-9 /TIMP-1	KATEGORI STADIUM	DIAGNOSIS HISTOPATOLOGI
1	ADB	36	II B	T3N0M0	383,219	135.8	2.82	STADIUM DINI	Adenocarcinoma
2	BS	38	I	T1N0M0	503,534	142.3	3.53	STADIUM DINI	Apokrin Cell Carcinoma
3	N	38	II B	T3N0M0	0,000	224.3	0	STADIUM DINI	Ca. Mamma
4	AM	41	II A	T2N0M0	283,265	112.7	2.51	STADIUM DINI	Invasive ductal
5	H	45	II A	T2N0M0	453,557	158.8	2.86	STADIUM DINI	Invasive ductal
6	AR	42	II A	T2N0M0	527,597	131.7	4.01	STADIUM DINI	Adenocarsinoma
7	ND	46	II B	T3N0M0	481,322	217	2.22	STADIUM DINI	Fibrokvstic disease
8	J	41	II A	T2N0M0	403,580	225.8	1.79	STADIUM DINI	Adenocarcinoma
9	HS	42	I	T1N0M0	1018,112	184.2	5.53	STADIUM DINI	Invasive ductal
10	S	43	II A	T2N0M0	560,915	182.9	3.07	STADIUM DINI	Invasive ductal
11	NS	52	II B	T3N0M0	644,210	144.7	4.45	STADIUM DINI	Adenocarcinoma
12	NJ	54	II B	T3N0M0	714,548	173.6	4.12	STADIUM DINI	Ca. Mamma
13	M	42	III B	T4cN2M0	932,966	189.6	4.92	STD.LANJUT	Adenocarcinoma
14	IR	42	III A	T3N1M0	538,703	158.8	3.39	STD.LANJUT	Invasive ductal
15	HB	38	III B	T4bN1M0	1280,954	539	2.38	STD.LANJUT	Ca. Mamma
16	MB	33	III C	T4cN3M0	246,245	643.9	0.38	STD.LANJUT	Adenocarcinoma
17	HW	43	III B	T4aN0M0	462,812	188.2	2.46	STD.LANJUT	Adenocarcinoma
18	HM	46	III B	T4aN2M0	609,041	179.5	3.39	STD.LANJUT	Invasif ductal carcinoma
19	SN	33	III B	T4N2M0	2400,809	409.3	5.87	STD.LANJUT	Ca Mammae
20	HN	51	III B	T4N0M0	1193,957	403.4	2.96	STD.LANJUT	Adenocarcinoma
21	NH	41	III B	T4N2M0	968,135	477.2	2.03	STD.LANJUT	Invasif ductal carcinoma
22	RT	42	III B	T4N2M0	560,915	329.4	1.7	STD.LANJUT	Adenocarcinoma
23	RS	33	III A	T3N1M0	932,966	347.2	2.69	STD.LANJUT	Adenocarcinoma
24	HE	43	III B	T4N0M0	1164,341	670.9	1.74	STD.LANJUT	Invasif ductal carcinoma

25	C	58	III B	T4N0M0	1210,616	526.8	2.3	STD.LANJUT	Adenocarcinoma
26	RD	49	III B	T4N0M0	1108,811	211.3	5.25	STD.LANJUT	Ca. Mammae
27	SG	41	III B	T4N1M0	932,966	145.9	6.4	STD.LANJUT	Invasif ductal carcinoma
28	IS	41	III B	T4N1M0	831,161	222.1	3.74	STD.LANJUT	Ca. Mammae
29	TD	36	III B	T4N1M0	818,204	130	6.29	STD.LANJUT	Invasive ductal
30	EB	42	III B	T4N0M0	969,986	366.4	2.65	STD.LANJUT	Adenocarsinoma
31	AT	36	III B	T4N1M0	605,339	139.9	4.33	STD.LANJUT	Adenocarsinoma
32	SR	47	III B	T4N0M0	266,606	155.1	1.72	STD.LANJUT	Adenocarsinoma
33	NY	39	III C	T4N3M0	1530,839	407.3	3.76	STD.LANJUT	Invasive ductal ca
34	MR	48	III B	T4 N0M0	671,975	141.1	4.76	STD.LANJUT	Adenocarsinoma
35	ADL	34	III B	T4N0M0	862,628	162	5.32	STD.LANJUT	Adenocarsinoma
36	HTJ	67	III C	T4N3M0	975,539	440.1	2.22	STD.LANJUT	Invasive ductal
37	EV	32	III B	T4N0M0	1003,304	169.7	5.91	STD.LANJUT	Adenocarsinoma
38	ISY	55	III B	T4N0M0	403,580	229.5	1.76	STD.LANJUT	ca. Mammae
39	SE	49	III C	T4N3M0	1284,656	344.5	3.73	STD.LANJUT	Invasive ductal
40	GW	48	III B	T4N0M0	159,248	129.4	1.23	STD.LANJUT	Adenocarcinoma
41	NI	41	III A	T3N1M0	1342,037	318	4.22	STD.LANJUT	Adenocarcinoma
42	NO	50	III B	T4N0M0	420,239	271.3	1.55	STD.LANJUT	Ca. Mammae
43	HLM	68	III B	T4N0M0	349,901	147.7	2.37	STD.LANJUT	Invasive ductal
44	SNT	34	III C	T4N3M0	577,574	301.8	1.91	STD.LANJUT	Adenocarcinoma
45	ER	34	IV	T4bN1M1	736,760	335.6	2.19	STD.LANJUT	Invasif ductal carcinoma
46	ELS	46	IV	T4N3M1	448,004	360	1.24	STD.LANJUT	Invasif ductal carcinoma
47	HAE	48	IV	T4cN3cM	274,010	604.4	0.45	STD.LANJUT	Ca. Mammae
48	AU	31	IV	T4N0M1	916,307	126.5	7.24	STD.LANJUT	Ca. Mammae
49	HAS	34	IV	T4N2M1	631,253	174.9	3.61	STD.LANJUT	Ca. Mammae bilateral
50	HSN	36	IV	T4N0M1	522,044	247.7	2.11	STD.LANJUT	Invasive ductal
51	KAM	66	IV	T4N1M1	831,161	127.7	6.51	STD.LANJUT	Ca. Mammae
52	JHE	53	IV	T4N3M1	1151,384	519.1	2.22	STD.LANJUT	Invasive ductal
53	JHU	64	IV	T4N0M1	224,033	255.4	0.88	STD.LANJUT	Invasive ductal
54	KAS	48	IV	T4N2M1	405,431	231.7	1.75	STD.LANJUT	Adenocarcinoma
55	MSY	39	IV	T4N1M1	1236,530	395.7	3.12	STD.LANJUT	Invasive ductal
56	HNW	31	IV	T4N2M1	1181,000	562.7	2.1	STD.LANJUT	Ca. Mammae

## Lampiran 4

**CURICULUM VITAE****I. Data Pribadi:**

1. Nama : Erviani zuhriah
2. NIP : 19720422 200202 2 004
3. Pangkat / Golongan : Penata Tk.1 / III d
4. Jenis Kelamin : Perempuan
5. Agama : Islam
6. Tempat / Tgl lahir : Ujung Pandang / 22 April 1972
7. Alamat : Jl. Daeng Siraju No. 68
8. Institusi : Dinas Kesehatan Kab. Muna

**II. Riwayat Pendidikan:**

1. SDN Komp Maradekaya I Makassar, lulus tahun 1985
2. SMPN 6 Makassar, lulus tahun 1988
3. SMAN 1 Makassar, lulus tahun 1991
4. Sarjana Kedokteran Fakultas Kedokteran Universitas Hasanuddin Makassar, Lulus tahun 1996
5. Profesi Dokter Fakultas Kedokteran Universitas Hasanuddin Makassar, Lulus tahun 1999
6. Program Pendidikan Dokter Spesialis Patologi Klinik Fakultas Kedokteran Universitas Hasanuddin Makassar, periode 1 Januari 2009
7. Program Pasca Sarjana Universitas Hasanuddin Makassar, periode 1 Januari 2009

**III. Riwayat Pekerjaan:**

1. Dokter PTT : Puskesmas Maligano Kabupaten Muna, Sul-Tra,  
1 Juli 1999 – 1 Agustus 2001  
Puskesmas Katobu Kabupaten Muna, Sul-Tra,  
1 Agustus 2001 – 1 Desember 2002
2. CPNS : Puskesmas Katobu Kabupaten Muna, Sul-Tra  
1 Desember 2002 – 1 Februari 2004
3. PNS : Puskesmas Katobu Kabupaten Muna, Sul-Tra  
1 Februari 2004 - Sekarang

**IV. Karya Ilmiah / Artikel yang telah dipublikasikan:**

Bakteri Aerob dan Uji kepekaan antimikroba pada IJCP & ML Vol.19  
No.1 November 2012